🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

6,931 results for “The” Clear

  1. Enzalutamide 40mg

    United Therapeutics Europe Ltd

    Metastatic Castration-Resistant Prostate Cancer (mCRPC)

    phase 2 small molecule active

    1 trial

  2. Epcoritamab

    ADC Therapeutics SA

    Large B-cell Lymphoma

    phase 2 small molecule active

    1 trial

  3. Epcoritamab

    United Therapeutics Europe Ltd

    Diffuse Large B-Cell Lymphoma, Not Otherwise Specified

    phase 2 mab active

    1 trial

  4. Epetraborole

    AN2 Therapeutics

    Mycobacterium Abscessus Infection

    phase 2 small molecule active

    1 trial

  5. Erbitux 5 mg/mL solution for infusion

    Disc Medicine

    Unknown primary tumour of the head and neck

    phase 2 small molecule active

    1 trial

  6. Erbitux 5 mg/mL solution for infusion, MVASI 25 mg/mL concentrate for solution for infusion, MVASI 25 mg/mL concentrate for solution for infusion, Braftovi 75 mg hard capsules

    The George Institute

    Metastatic colorectal cancer

    phase 2 small molecule active

    1 trial

  7. Eribulin mesylate

    HALOZYME THERAPEUTICS, INC.

    Metastatic Breast Cancer

    phase 2 small molecule terminated

    1 trial

  8. Erlotinib

    United Therapeutics Europe Ltd

    Non-Small Cell Lung Cancer

    phase 2 small molecule completed

    1 trial

  9. Erlotinib

    United Therapeutics Europe Ltd

    Lung Cancer

    phase 2 small molecule completed

    1 trial

  10. Erwinaze® (Asparaginase Erwinia Chrysanthemi)/Erwinase® (Crisantaspase)

    Jazz Pharmaceuticals Ireland Limited

    Acute Lymphoblastic Leukemia (ALL)/Lymphoblastic Lymphoma (LBL)

    phase 2 small molecule terminated

    1 trial

  11. Etanercept

    United Therapeutics Europe Ltd

    Lupus Erythematosus, Discoid

    phase 2 small molecule completed

    1 trial

  12. Eteplirsen

    Sarepta Therapeutics

    Duchenne Muscular Dystrophy

    phase 2 small molecule terminated

    2 trials

  13. Etirinotecan pegol

    Nektar Therapeutics UK Limited

    Anaplastic Astrocytomas

    phase 2 small molecule completed

    1 trial

  14. Etoposide

    The First People's Hospital of Lianyungang

    Small Cell Lung Cancer Limited Stage

    phase 2 small molecule active

    1 trial

  15. Evaluation of 64Cu-ATSM PET/CT as a predictor of response to neoadjuvant therapy in locally advanced rectal cancer (TEP-64Cu-ATSM-Rectum)

    CERO THERAPEUTICS HOLDINGS, INC.

    Rectal adenocarcinoma

    phase 2 other active

    1 trial

  16. Evaluation of the safety and efficacy of Continuous Dopaminergic Stimulation by intracerebroventricular administration of anaerobically conserved dopamine in Parkinson's disease at the motor fluctuation stage: Single-center pilot study

    Lacuna Pharma Pty Ltd

    Parkinson's disease

    phase 2 other active

    1 trial

  17. Exercise Programme

    United Therapeutics Europe Ltd

    Parkinson's Disease

    phase 2 other completed

    1 trial

  18. Exercise Training

    United Therapeutics Europe Ltd

    Breast Cancer

    phase 2 other completed

    1 trial

  19. Exicorilant

    CORCEPT THERAPEUTICS INC

    Metastatic Castration-Resistant Prostate Cancer

    phase 2 small molecule terminated

    1 trial

  20. Experimental

    The First People's Hospital of Lianyungang

    Locally Advanced Rectal Cancer (LARC)

    phase 2 small molecule active

    1 trial

  21. Experimental: tislelizumab+anlotinib

    The First People's Hospital of Lianyungang

    Thymic Carcinoma

    phase 2 small molecule active

    1 trial

  22. Extended Access of Momelotinib for Subjects with Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ETMF)

    GlaxoSmithKline

    Primary Myelofibrosis (PMF), Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)

    phase 2 other active

    1 trial

  23. Extended-release Onapristone

    Context Therapeutics

    Refractory Endometrial Adenocarcinoma

    phase 2 small molecule active

    1 trial

  24. Ezutromid

    Summit Therapeutics

    Duchenne Muscular Dystrophy

    phase 2 small molecule terminated

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources